Ingenuity, creativity and collaboration above all were essential to overcome them. For many pharmaceutical companies, a key solution to tackle COVID-19 issues was to outsource many of the technical processes that accompany pharmaceutical production to contract development and manufacturing organisations (CDMOs).
From the development and commercialisation of vaccine candidates and other treatments, to the transfer process itself, as well as measures to improve the product lifecycle, outsourcing supported companies in freeing up crucial capacity and accelerating the delivery of vital new therapies.
This surge in outsourcing – as well as the success of the vaccine roll-out – has highlighted the unique benefits of collaboration between CDMOs and pharmaceutical companies in significantly reducing project timeframes.
In a recent Q&A with The Medicine Maker, Michael Isele, General Manager at Recipharm explores the impact of the last 18 months on pharmaceutical companies. He discusses the role CDMOs have played in helping drug developers overcome challenges, and looks at how the industry’s relationship with outsourcing has changed.